A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
- Registration Number
- NCT00415155
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Diagnosed with hepatocellular cancer
- Discontinued all previous therapies
- At least 18 years of age
Read More
Exclusion Criteria
- Have other treatment options that are potentially curative or effective--such as surgical resection, liver transplant or percutaneous ablation, and/or transcatheter arterial embolization.
- Transplanted liver
- HIV positive
- More than 2 previous systemic chemotherapy treatments
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A LY2181308 -
- Primary Outcome Measures
Name Time Method Phase 1: Determine recommended dose every cycle Phase 2: Time to progression baseline to measured progressive disease
- Secondary Outcome Measures
Name Time Method Phase 1: Safety every cycle Phase 2: Overall Survival Baseline to date of death from any cause Phase 2: Response rate Baseline to measured PD Phase 2: Pharmacokinetics Cycle 1 and Cycle 2 Phase 2: Safety every cycle
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇪🇸Pamplona, Spain